Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/9/2019
SIETES contiene 92806 citas

 1 a 20 de 23 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
2.Enlace a cita original Cita con resumen
Montalescot G, Sabatine MS. Oral dual antiplatelet therapy: what have we learnt from recent trials?. Eur Heart J 2015:6 de agosto. [Ref.ID 99343]
3. Cita con resumen
Bellemain-Appaix A, Kerneis M, O'Connor SA, Silvain J, Cucherat M, Beygui F, Barthélémy O, Collet J-P, Jacq L, Bernasconi F, Montalescot G, for the ACTION Study Group. Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ 2014;349:g6269. [Ref.ID 98292]
4.Tiene citas relacionadas Cita con resumen
Gagne JJ, Bykov K, Choudhry NK, Toomey TJ, Connolly JG, Avorn J. Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ 2013;347:11. [Ref.ID 96346]
5.Tiene citas relacionadas Cita con resumen
Hirschl MM. Smoking status and the effects of antiplatelet drugs. BMJ 2013;347:10. [Ref.ID 96345]
6. Cita con resumen
Holtzman NA. Chronicle of an unforetold death. Arch Intern Med 2012;172:1174-8. [Ref.ID 93591]
7. Cita con resumen
Gurbel PA, Nolin TD, Tantry US. Clopidogrel efficacy and cigarette smoking status. JAMA 2012;307:2495-6. [Ref.ID 93316]
8.Enlace a cita original
Passacquale G, Ferro A. Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. BMJ 2011;342:1415-20. [Ref.ID 90956]
9.Tiene citas relacionadas Cita con resumen
Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction?. Lancet 2009;374:952-4. [Ref.ID 86836]
10.Tiene citas relacionadas Cita con resumen
O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97. [Ref.ID 86536]
11.Tiene citas relacionadas Cita con resumen
Chua D, Ignaszewski A. Clopidogrel. Authors' reply. BMJ 2009;338:1226-7. [Ref.ID 85961]
12. Cita con resumen
Anónimo. Antiplatelet therapy for patients with stents. Med Lett Drugs Ther 2008;50:61-3. [Ref.ID 83808]
14.Tiene citas relacionadas Cita con resumen
Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet 2006;367:1877-8. [Ref.ID 77184]
15. Cita con resumen
Anónimo. Clopidogrel (Plavix) revisited. Med Lett Drugs Ther 2006;48:29-31. [Ref.ID 76844]
16.Tiene citas relacionadas
Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. the editorialists reply. N Engl J Med 2004;350:2102. [Ref.ID 70047]
17.Tiene citas relacionadas
Steimle AE. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004;350:2101-2. [Ref.ID 70046]
18.Tiene citas relacionadas
Stone GW, Ellis SG, Russell M E. Paclitaxel-eluting coronary stents. The authors reply. N Engl J Med 2004;350:2100. [Ref.ID 70042]
19.Tiene citas relacionadas
Ajani AE, Waksman R. Paclitaxel-eluting coronary stents. N Engl J Med 2004;350:2099-100. [Ref.ID 70041]
Levine GN, Kern MJ, Berger PB, Brown DL, Klein LW, Kereiakes DJ, Sanborn TA, Jacobs AK, for the American Heart Association Diagnostic and Interventional Catheterization Committee and Council on Clinical Cardiology. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003;139:123-36. [Ref.ID 66884]
Seleccionar todas
 1 a 20 de 23 siguiente >>